Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations.
Ischemic heart disease (IHD) is the leading cause of death worldwide. Novel cardioprotective strategies are therefore required to improve clinical outcomes in patients with IHD. Although a large number of novel cardioprotective strategies have been discovered in the research laboratory, their translation to the clinical setting has been largely disappointing. The reason for this failure can be attributed to a number of factors including the inadequacy of the animal ischemia-reperfusion injury models used in the preclinical cardioprotection studies and the inappropriate design and execution of the clinical cardioprotection studies. This important issue was the main topic of discussion of the UCL-Hatter Cardiovascular Institute 6th International Cardioprotection Workshop, the outcome of which has been published in this article as the "Hatter Workshop Recommendations". These have been proposed to provide guidance on the design and execution of both preclinical and clinical cardioprotection studies in order to facilitate the translation of future novel cardioprotective strategies for patient benefit.
Hausenloy
Derek J
DJ
The Hatter Cardiovascular Institute, University College London Hospitals and Medical School, 67 Chenies Mews, London, WC1E 6HX, UK.
Baxter
Gary
G
Bell
Robert
R
Bøtker
Hans Erik
HE
Davidson
Sean M
SM
Downey
James
J
Heusch
Gerd
G
Kitakaze
Masafumi
M
Lecour
Sandrine
S
Mentzer
Robert
R
Mocanu
Mihaela M
MM
Ovize
Michel
M
Schulz
Rainer
R
Shannon
Richard
R
Walker
Malcolm
M
Walkinshaw
Gail
G
Yellon
Derek M
DM
D000367:Age Factors; D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D057775:Ischemic Postconditioning; D019157:Ischemic Preconditioning, Myocardial; D009203:Myocardial Infarction / Q000517:prevention & control*; D017202:Myocardial Ischemia / Q000628:therapy*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D012737:Sex Factors; D013045:Species Specificity; D057170:Translational Research, Biomedical; D016896:Treatment Outcome
D002317:Cardiovascular Agents